Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

被引：11

作者：

Marouf, Amira ^{[1
,2
,3
]}

Cottereau, Anne Segolene ^{[2
,4
]}

Kanoun, Salim ^{[5
]}

Deschamps, Paul ^{[1
,2
]}

Meignan, Michel ^{[6
,7
]}

Franchi, Patricia ^{[1
,2
]}

Sibon, David ^{[8
,9
]}

Antoine, Clara ^{[6
]}

Gastinne, Thomas ^{[10
]}

Borel, Cecile ^{[11
]}

Hammoud, Mohammad ^{[12
]}

Sicard, Guillaume ^{[13
]}

Gille, Romane ^{[14
]}

Cavalieri, Doriane ^{[15
]}

Stamatoullas, Aspasia ^{[16
]}

Filliatre-Clement, Lauriane ^{[16
]}

Lazarovici, Julien ^{[17
]}

Chauchet, Adrien ^{[18
]}

Fornecker, Luc-Matthieu ^{[19
,20
,21
]}

Amorin, Sandy ^{[22
]}

Rocquet, Mathieu ^{[1
]}

Raus, Nicole ^{[23
,24
]}

Burroni, Barbara ^{[25
,26
]}

Rubio, Marie Therese ^{[24
,27
,28
]}

Bouscary, Didier ^{[1
,2
,29
]}

Quittet, Philippe ^{[30
]}

Casasnovas, Rene Olivier ^{[31
,32
]}

Brice, Pauline ^{[33
]}

Ghesquieres, Herve ^{[34
]}

Tamburini, Jerome ^{[1
,2
,29
,35
]}

Deau, Benedicte ^{[1
,2
]}

机构：

[1] Hop Cochin, AP HP, Dept Hematol, Paris, France

[2] Univ Paris, Paris, France

[3] INSERM, UMR 1163, Inst Imagine, Paris, France

[4] Hop Cochin, AP HP, Dept Nucl Med, Paris, France

[5] INSERM, Canc Res Ctr Toulouse CRCT, Team 9, UMR 1037, Toulouse, France

[6] Hop Henri Mondor, Lymphoma Study Assoc Imaging, Lymphoma Acad Res Org LYSARC, Creteil, France

[7] Paris Est Univ, Creteil, France

[8] Necker Univ Hosp, Hematol Dept, AP HP, Paris, France

[9] Necker Univ Hosp, Inst Necker Enfants Malades, AP HP, INSERM U1151, Paris, France

[10] Nantes Univ Hosp, Dept Hematol, Nantes, France

[11] Inst Univ Canc Toulouse Oncopole, Dept Hematol, Toulouse, France

[12] Hop Henri Mondor, Lymphoid Malignancies Unit, Creteil, France

[13] Aix Marseille Univ, Dept Hematol, Marseille, France

[14] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[15] Ctr Hosp Univ CHU Estaing, Dept Hematol, Clermont Ferrand, France

[16] Clin Louis Pasteur, Dept Hematol, Nancy, France

[17] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[18] CHU Besancon, Dept Hematol, Besancon, France

[19] Strasbourg Univ Hosp, Strasbourg, France

[20] INSERM S 1113, Strasbourg, France

[21] Strasbourg Univ, Fac Med, Strasbourg, France

[22] Hop St Vincent de Paul, Dept Hematol, Lille, France

[23] Hop Lyon Sud, Dept Hematol, Pierre Benite, France

[24] Soc Francophone Greffe Moelle & Therapie Cellulai, Pierre Benite, France

[25] Hop Cochin, AP HP, Serv Pathol, Paris, France

[26] Paris Univ, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France

[27] Hop Brabois, CHRU Nancy, Dept Hematol, Nancy, France

[28] Biopole Univ Lorraine, CNRS UMR 7365, Equipe 6, Vandoeuvre Les Nancy, France

[29] INSERM, Inst Cochin, U1016, Paris, France

[30] Univ Montpellier, Dept Hematol, Montpellier, France

[31] Dijon Univ Hosp, Dept Hematol, Dijon, France

[32] CHU Dijon, INSERM UMR 1231, Dijon, France

[33] Hop St Louis, CHU Paris GH St Louis Lariboisiere F Widal, Dept Hematol, Paris, France

[34] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France

[35] Univ Geneva, Fac Med, Translat Res Ctr Oncohematol, Geneva 4, Switzerland

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 07期

关键词：

THERAPY; COMBINATION; 2ND-LINE;

D O I：

10.3324/haematol.2021.279564

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1681 / 1686

页数：6

共 50 条

[31] SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY
Walewski, J.
Hellmann, A.
Siritanaratkul, N.
Ozsan, G. H.
Ozcan, M.
Chuncharunee, S.
Goh, A. S.
Jurczak, W.
Koren, J.
Wang, B.
Singh, S.
Huebner, D.
Engert, A.
HAEMATOLOGICA, 2016, 101 : 56 - 56
[32] Outcomes of Pediatric Relapsed/Refractory Hodgkin Lymphoma Post Autologous Stem Cell Transplant
Sarangarajan, Sanjana
Singh, Shivani Deep
Gupta, Aditya Kumar
Meena, Jagdish Prasad
Seth, Rachna
INDIAN JOURNAL OF PEDIATRICS, 2025, 92 (03): : 308 - 308
[33] BRENTUXIMAB VEDOTIN (SGN-35) IN HODGKIN LYMPHOMA PATIENTS WITH RELAPSED AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM-CELL TRANSPLANTATION
Erdem, G.
Karadurmus, N.
Ozaydin, S.
Karacalioglu, A. O.
Yeginer, C.
Turker, T.
Ozturk, M.
Ataergin, S.
Nevruz, O.
Cetin, T.
Arpaci, F.
BONE MARROW TRANSPLANTATION, 2014, 49 : S445 - S445
[34] Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era
Anderlini, Paolo
Saliba, Rima
Ledesma, Celina
Chancoco, Christina M.
Alexander, Tamera R.
Alousi, Amin M.
Hosing, Chitra
Khouri, Issa F.
Nieto, Yago
Popat, Uday R.
Shpall, Elizabeth J.
Fanale, Michelle A.
Oki, Yasuhiro
Romaguera, Jorge E.
Neelapu, Sattva S.
Younes, Anas
Champlin, Richard E.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S72 - S72
[35] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
Zagadailov, E. A.
Corman, S.
Hagan, M.
Chirikov, V.
Johnson, C.
Macahilig, C.
Dalal, M. R.
Broeckelmann, P. J.
HAEMATOLOGICA, 2016, 101 : 98 - 99
[36] BENEFIT OF TANDEM STEM CELL TRANSPLANTATION FOR HIGH RISK RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: A FRENCH PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY ON 120 PATIENTS
Deau, B.
Amorim, S.
Perrot, A.
Quittet, P.
Cornillon, J.
Chaoui, D.
Marolleau, J. P.
Fornecker, L. -M.
Robin, M.
Brice, P.
HAEMATOLOGICA, 2016, 101 : 45 - 45
[37] COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN TAIWAN
Zou, D.
Kendall, R.
Lin, Q.
Huang, Y.
Tieng, J.
Tseng, J.
Sajosi, P.
VALUE IN HEALTH, 2016, 19 (07) : A888 - A888
[38] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
Fukuhara, Noriko
Yamamoto, Go
Tsujimura, Hideki
Chou, Takaaki
Shibayama, Hirohiko
Yanai, Tomoko
Shibuya, Kazunori
Izutsu, Koji
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
[39] Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant
Karuturi, Meghan S.
Arai, Sally
Chen, Robert W.
Gopal, Ajay K.
Feng, Lei
Yuan, Ying
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Ramchandren, Radhakrishnan
Bartlet, Nancy L.
Cheson, Bruce D.
Forero-Torres, Andres
Moskowitz, Craig H.
Connors, Joseph M.
Fanale, Michelle A.
de Vos, Sven
Engert, Andreas
Illidge, Tim
Borchmann, Peter
Morschhauser, Franck
Horning, Sandra J.
Younes, Anas
BLOOD, 2012, 120 (21)
[40] Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study
Akay, Olga Meltem
Ozbalak, Murat
Pehlivan, Mustafa
Yildiz, Birol
Uzay, Ant
Yigenoglu, Tugce Nur
Elverdi, Tugrul
Kaynar, Leylagul
Ayyildiz, Orhan
Yonal Hindilerden, Ipek
Goksoy, Hasan Sami
Izmir Guner, Sebnem
Gunes, Ahmet Kursad
Sonmez, Mehmet
Kurt Yuksel, Meltem
Civriz Bozdag, Sinem
Ozkurt, Zubeyde Nur
Toptas, Tayfur
Dogu, Mehmet Hilmi
Salim, Ozan
Saydam, Guray
Yavasoglu, Irfan
Ayli, Meltem
Ozet, Gulsum
Albayrak, Murat
Birtas Atesoglu, Elif
Toprak, Selami K.
Yildirim, Rahsan
Mehtap, Ozgur
Kalayoglu Besisik, Sevgi
Nalcaci, Meliha
Altuntas, Fevzi
Ferhanoglu, Burhan
HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 498 - 505

← 1 2 3 4 5 →